Fig. 5.

Senolytic therapy and caloric restriction (CR) improve intestinal barrier biomarkers without changes in the mucosal or fecal microbiomes. A Lipopolysaccharide binding protein (LBP)-1 significantly reduced with intermittent dasatinib (D) and quercetin (Q) administration, and an interaction with CR augmented this improvement. B Circulatory fatty acid binding protein (FABP)-1 supports intestinal barrier improvements with a trend towards reduced levels across the study. C)Immunoglobulin (Ig) A in circulation additionally supports the improvement in intestinal barrier function with D + Q and the positive effect of CR on these endpoints. Colon mucosal microbiome alpha diversity profiles were comparable at baseline (D, p = 0.24 and E, p = 0.25) and at study end (6 months; F, p = 0.06 and G, p = 0.38) between the vehicle group (VEH) and the dasatinib plus quercetin (D + Q) animals. Similarly, diversity was comparable at study start (H, p = 0.13 and I, p = 0.19) and unchanged by treatment (J, p = 0.90 and K, p = 0.73) in the fecal microbiome profiles. All values presented are adjusted means ± SEM